DIAZEPINOMICIN Uses, Dosage, Side Effects and more
DIAZEPINOMICIN has been used in trials studying the treatment of Glioblastoma Multiforme. It is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours like the well known chemotherapeutics, doxorubicin and mitomycin C. DIAZEPINOMICIN is a natural product derived from a non-pathogenic micro-organism. Discovered using Thallion’s DECIPHER technology, diazepinomicin has completed preclinical studies conducted by the National Cancer Institute and Thallion to establish safety and efficacy in animal and in vitro models.
| Attribute | Details |
|---|---|
| Trade Name | DIAZEPINOMICIN |
| Generic | Diazepinomicin |
| Diazepinomicin Other Names | DIAZEPINOMICIN |
| Type | |
| Formula | C28H34N2O4 |
| Weight | Average: 462.59 Monoisotopic: 462.251857583 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How DIAZEPINOMICIN works
DIAZEPINOMICIN demonstrates broad in vitro cytotoxic activity across a diverse panel of tumour cell lines and in vivo efficacy in a number of xenograft tumour models. Preclinical data suggest that diazepinomicin is a targeted anti-cancer agent with dual activity: selective binding to the peripheral benzodiazepine receptor (PBR) and inhibition of the Ras-MAPK pathway.
